Company Overview
Karyopharm Therapeutics Inc. operates as a commercial-stage pharmaceutical entity dedicated to the discovery, development, and commercialization of drugs targeting nuclear export mechanisms for the treatment of cancer and other diseases within the United States. The company functions within the Healthcare sector, specifically in the Biotechnology industry, where innovation in small molecule therapeutics is central to its operational model. As of the latest data, the firm employs 228 individuals and holds a market capitalization of $123.54M, generating annual revenue of $146.07M. These valuation and revenue figures indicate that Karyopharm is a mid-sized player in the biotechnology landscape, possessing a tangible asset base sufficient to sustain operations but lacking the massive market cap associated with large-cap established pharmaceutical giants.
Financial Health
Karyopharm Therapeutics reported revenue of $146.07M over the trailing twelve months, yet it recorded a net income of -$196,039,008, a significant gap that reveals a highly expansive cost structure where operating expenses and other deductions far exceed gross profits. This disparity is further highlighted by an EBITDA of -$90,411,000, suggesting that the company's core business operations are currently generating negative cash earnings before interest, taxes, depreciation, and amortization. The firm maintains a free cash flow of -$49,426,500, which indicates a reliance on external capital sources to fund ongoing research, development, and commercialization efforts rather than self-funding from internal cash generation. Margin analysis shows a gross margin of 9.9%, an operating margin of -52.4%, and a profit margin of -134.2%, collectively illustrating that the company struggles to convert sales into operating profit and faces substantial inefficiencies or high R&D burn relative to revenue. On the liability side, the company holds $63.74M in cash against $305.94M in debt, resulting in a debt-to-equity ratio that is not applicable due to the lack of positive equity, which points to a leveraged balance sheet structure rather than a conservative one. Liquidity is assessed via a current ratio of 1.12, indicating that the company holds just enough current assets to cover its current liabilities, leaving little room for error in its short-term financial management. Return on equity is not applicable, while the return on assets stands at -41.6%, a metric that reveals management has not yet achieved profitability in utilizing the company's total asset base to generate positive returns for shareholders.
Valuation Assessment
The valuation metrics for Karyopharm Therapeutics present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of -2.18, implying that the market does not yet anticipate a normalized earnings trajectory that would support a standard positive multiple based on current profitability. The price-to-book ratio is recorded at -0.34, a negative figure that typically indicates the market values the company significantly below its book value, often due to accumulated losses or the high risk premium associated with its biotechnology assets. Alternative valuation metrics such as the price-to-sales ratio of 0.85 and an EV/EBITDA of -3.79 suggest that the stock is priced relative to its revenue generation rather than earnings power, which is common for pre-profitable biotech firms but implies high sensitivity to future commercial success. The stock has traded between a 52-week high of $10.99 and a 52-week low of $3.51; without a specific current price provided in the facts, the valuation context relies on these bounds to show the significant volatility and potential discount or premium relative to recent trading extremes. The beta value of 0.20 indicates that the stock's price volatility is substantially lower than the broader market, suggesting that the asset class may offer a defensive characteristic or that the stock price is less sensitive to general market fluctuations compared to large-cap equities.
Growth & Income
Karyopharm Therapeutics demonstrated a revenue growth rate of 11.6% year-over-year, while earnings growth is N/A, indicating that the company is expanding its top line but has not yet achieved the consistent profitability required to calculate traditional earnings growth metrics. This divergence implies that the company is prioritizing market share expansion and product launch velocity over immediate profit generation, a common strategy in the biotechnology sector where cash burn is high during the commercial ramp-up phase. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm retains all of its earnings to reinvest into research, development, and commercialization activities rather than distributing cash to shareholders. The overall growth and income profile for Karyopharm Therapeutics is characterized by positive revenue expansion coupled with negative earnings, reflecting a high-risk, high-reward investment thesis typical of commercial-stage pharmaceutical companies that have not yet reached a path to sustained profitability.